A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

por Smith, David C., Chugh, Rashmi, Patnaik, Amita, Papadopoulos, Kyriakos P., Wang, Min, Kapoun, Ann M., Xu, Lu, Dupont, Jakob, Stagg, Robert J., Tolcher, Anthony
Publicado en Invest New Drugs (2018)

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

por Wang-Gillam, Andrea, Tew, William P., Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Sternas, Lars, Buzenet, Giliane, Sosman, Jeffrey A., Spriggs, David R., Lockhart, Albert Craig
Publicado 2011

Phase 1 Study of VEGF Trap (Aflibercept) Administered Subcutaneously to Patients with Advanced Solid Tumors

por Tew, William P., Gordon, Michael, Murren, John, Dupont, Jakob, Pezzulli, Sandra, Aghajanian, Carol, Sabbatini, Paul, Mendelson, David, Schwartz, Lawrence, Gettinger, Scott, Psyrri, Amanda, Cedarbaum, Jesse M., Spriggs, David R.
Publicado 2009

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

por Zang, Xingxing, Sullivan, Peggy S, Soslow, Robert A, Waitz, Rebecca, Reuter, Victor E, Wilton, Andrew, Thaler, Howard T, Arul, Manonmani, Slovin, Susan F, Wei, Joyce, Spriggs, David R, Dupont, Jakob, Allison, James P
Publicado 2010

Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of KOS-862 (Epothilone D) in Patients with Advanced Solid Tumors and Lymphoma

por Konner, Jason, Grisham, Rachel N., Park, Jae, O’Connor, Owen A., Cropp, Gillian, Johnson, Robert, Hannah, Alison L., Hensley, Martee L., Sabbatini, Paul, Miranov, Svetlana, Danishefsky, Samuel, Hyman, David, Spriggs, David R., Dupont, Jakob, Aghajanian, Carol
Publicado 2011

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

por Lockhart, A. Craig, Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Chevalier, Paul, Sternas, Lars, Buzenet, Giliane, Koehler, Elizabeth, Sosman, Jeffrey A., Schwartz, Lawrence H., Gultekin, David H., Koutcher, Jason A., Donnelly, Edwin F., Andal, Ric, Dancy, Isabelle, Spriggs, David R., Tew, William P.
Publicado 2010

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Res...

por Ferrarotto, Renata, Mitani, Yoshitsugu, Diao, Lixia, Guijarro, Irene, Wang, Jing, Zweidler-McKay, Patrick, Bell, Diana, William, William N., Glisson, Bonnie S., Wick, Michael J., Kapoun, Ann M., Patnaik, Amita, Eckhardt, Gail, Munster, Pamela, Faoro, Leonardo, Dupont, Jakob, Lee, J. Jack, Futreal, Andrew, El-Naggar, Adel K., Heymach, John V.
Publicado en J Clin Oncol (2017)

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

por Hu, Zishuo Ian, Bendell, Johanna C., Bullock, Andrea, LoConte, Noelle K., Hatoum, Hassan, Ritch, Paul, Hool, Hugo, Leach, Joseph W., Sanchez, James, Sohal, Davendra P. S., Strickler, John, Patel, Ravindranath, Wang‐Gillam, Andrea, Firdaus, Irfan, Yu, Kenneth H., Kapoun, Ann M., Holmgren, Eric, Zhou, Lei, Dupont, Jakob, Picozzi, Vincent, Sahai, Vaibhav, O'Reilly, Eileen M.
Publicado en Cancer Med (2019)